The Three P’s: Parotid, PD-L1, and Pembrolizumab

Wiggins, Amanda; Arter, Zhaohui; Kerns, Tamie

doi:10.1155/2019/2305315

Cited by 1 publication

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A search of PubMed for articles on the use of pembrolizumab for recurrent or metastatic parotid cancer yielded a single case of undifferentiated parotid cancer (5).…”

Section: Discussionmentioning

confidence: 99%

“…A case report documented the effectiveness of pembrolizumab in the treatment of an undifferentiated parotid cancer; however, this has not been described yet for acinic cell carcinoma (5). In addition, Okamoto et al (6) reported that nivolumab, an ICI, significantly prolonged OS in patients with recurrent and metastatic head and neck cancer, including SCC and non-SCC, when PD-L1 expression was ≥40%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Case of Recurrent Metastatic Parotid Acinic Cell Carcinoma Responsive to Pembrolizumab

Yamashita

Okamoto

Shimizu

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background: No clear chemotherapy regimen for recurrent or metastatic parotid cancer exists. We describe our experience with pembrolizumab to treat recurrent or metastatic parotid cancer. Case Report: A 73-year-old woman with swelling in the lower part of the right ear for 10 years before surgery was diagnosed with right parotid cancer, underwent total right parotidectomy, and reported recurrence. She requested treatment due to diminished quality of life caused by neurological symptoms. Tissue was collected from the recurrent lesion and its combined positive score was >20; pembrolizumab was started 9 years postoperatively. Results: To date, the patient has received 14 cycles of pembrolizumab. Evaluation by computed tomography showed a partial response to treatment. The only immune-related adverse event was grade 1 pneumonia in both lungs. Conclusion: Significant response to pembrolizumab in recurrent or metastatic parotid cancer is rarely reported, making this a remarkable case. We plan to continue pembrolizumab administration.

show abstract

“…A search of PubMed for articles on the use of pembrolizumab for recurrent or metastatic parotid cancer yielded a single case of undifferentiated parotid cancer (5).…”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%